This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Results of the review
The following average probability values for experimental strategy 1 were estimated from the literature. Surgery after benign (grade 2) US result, 0.126 (range: 0.098 -0.160).
False-negative result surgery after benign US result, 0.023 (range: 0.001 -0.106).
False-negative result of discharge after normal (grade 1) US result, 0.000 (range: 0.000 -0.050).
The following average probability values for experimental strategy 2 were estimated. Surgery after benign (grade 2) US result, 0.000 (range: 0.000 -0.050).
False-negative result surgery after benign US result, 0.000 (range: 0.000 -0.050).
The following average probability values for experimental strategy 3 were estimated. 
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The following average probability values common to all strategies were estimated. 
Methods used to derive estimates of effectiveness
The opinions of an expert panel were used to derive some unpublished clinical estimates used in the decision model.
Estimates of effectiveness and key assumptions
For example, the following estimates for experimental strategy 1 were made. Other assumptions were made for strategies 2 and 3 and were reported in the article.
Measure of benefits used in the economic analysis
The summary benefit measure used was the estimated LE associated with each diagnostic strategy. This was derived
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Direct costs
The analysis of the costs took the perspective of the health care system. Thus, only the direct medical costs of FNAC, US, core needle biopsy, excision biopsy, curative surgery, adjuvant therapy, treatment for local recurrence, palliative care and treatment of disease-free patients were considered. For each category of costs, the main cost components were reported. These included hospital or nursing care, diagnostic radiology, pathology, surgery, radiotherapy, hormone therapy, chemotherapy and specialist control. The unit costs were not explicitly presented separately from the quantities of resources but, since resource use depended on different pathways of the model, were reflected by the probabilities of events. Also, unit costs were reported for most items. Resource use was estimated from published studies, while the costs were estimated from the Dutch Health Care Insurance Board, the Hospital Information System of the Maastricht University Hospital, the Pharmacotherapeutic Guidelines 2000-2001, and the Dutch Radiotherapy Guidelines for Breast Cancer. Discounting was not relevant as the costs per patient were incurred during a short timeframe. The price year was 2000.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not considered in the analysis.
Currency Euros (EUR).

Sensitivity analysis
A univariate sensitivity analysis was carried out on almost all model inputs to assess the robustness of the costs and benefits. Ranges of values were based on 90% confidence intervals for clinical data. For deterministic inputs, ranges were derived using +/-50% of the base-case value. A threshold analysis was also performed to identify the values at which the preferred strategy would alter.
Estimated benefits used in the economic analysis
The expected LE was 31.0 years with all diagnostic strategies.
Cost results
The total costs were:
EUR 3,087 with the conventional strategy (EUR 182 for diagnosis, EUR 1,472 for treatment and EUR 1,433 for follow-up care), EUR 3,047 (EUR 165 for diagnosis, EUR 1,449 for treatment and EUR 1,433 for follow-up care) with experimental strategy 1, EUR 3,512 (EUR 294 for diagnosis, EUR 1,785 for treatment and EUR 1,433 for follow-up care) with experimental strategy 2, and EUR 3,013 (EUR 122 for diagnosis, EUR 1,458 for treatment and EUR 1,433 for follow-up care) with experimental strategy 3.
